[HTML][HTML] Epicutaneous Staphylococcus aureus induces IL-36 to enhance IgE production and ensuing allergic disease

GJ Patrick, H Liu, MP Alphonse… - The Journal of …, 2021 - Am Soc Clin Investig
GJ Patrick, H Liu, MP Alphonse, DA Dikeman, C Youn, JC Otterson, Y Wang, A Ravipati
The Journal of clinical investigation, 2021Am Soc Clin Investig
IgE induced by type 2 immune responses in atopic dermatitis is implicated in the
progression of atopic dermatitis to other allergic diseases, including food allergies, allergic
rhinitis, and asthma. However, the keratinocyte-derived signals that promote IgE and
ensuing allergic diseases remain unclear. Herein, in a mouse model of atopic dermatitis–
like skin inflammation induced by epicutaneous Staphylococcus aureus exposure,
keratinocyte release of IL‑36α along with IL-4 triggered B cell IgE class-switching, plasma …
IgE induced by type 2 immune responses in atopic dermatitis is implicated in the progression of atopic dermatitis to other allergic diseases, including food allergies, allergic rhinitis, and asthma. However, the keratinocyte-derived signals that promote IgE and ensuing allergic diseases remain unclear. Herein, in a mouse model of atopic dermatitis–like skin inflammation induced by epicutaneous Staphylococcus aureus exposure, keratinocyte release of IL‑36α along with IL-4 triggered B cell IgE class-switching, plasma cell differentiation, and increased serum IgE levels—all of which were abrogated in IL-36R–deficient mice or anti-IL‑36R–blocking antibody–treated mice. Moreover, skin allergen sensitization during S. aureus epicutaneous exposure-induced IL-36 responses was required for the development of allergen-specific lung inflammation. In translating these findings, elevated IL‑36 cytokines in human atopic dermatitis skin and in IL‑36 receptor antagonist–deficiency patients coincided with increased serum IgE levels. Collectively, keratinocyte-initiated IL‑36 responses represent a key mechanism and potential therapeutic target against allergic diseases.
The Journal of Clinical Investigation